Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brandon Miner

MOHS-Micrographic Surgery Idaho Falls, ID Doctor of Osteopathy

NPI 1528279189 CMS profile 720154

2085 Providence Way, Idaho Falls, ID 83404

Open in the dashboard

General payments

$5,235

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$140,644 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Brandon Miner of Idaho Falls, ID is reported in the CMS Open Payments database as having received $5,235 across 247 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $140,644 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369 15
2024 General $687 37
2023 General $797 41
2022 General $843 48
2021 General $822 43
2020 General $428 24
2019 General $1,290 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brandon Miner
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Brandon Miner were reported at $369. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Brandon Miner MOHS-Micrographic Surgery median Middle half National median
2019 $1,290 $316 $106–$785 $163
2020 $428 $162 $68–$412 $114
2021 $822 $243 $87–$654 $132
2022 $843 $300 $102–$887 $149
2023 $797 $364 $125–$1,010 $160
2024 $687 $445 $142–$1,108 $164
2025 $369 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,509 85 payments
  2. Novartis Pharmaceuticals Corporation $739 42 payments
  3. Regeneron Pharmaceuticals, Inc. $526 2 payments
  4. Janssen Biotech, Inc. $365 13 payments
  5. Genzyme Corporation $302 16 payments
  6. UCB, Inc. $257 13 payments
  7. Amgen Inc. $249 12 payments
  8. Regeneron Healthcare Solutions, Inc. $243 10 payments
  9. LEO Pharma Inc. $187 9 payments
  10. Lilly USA, LLC $157 6 payments
  11. Other $701 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,035 245 payments
  2. Education $200 2 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,012 64 payments
  2. HUMIRA $616 31 payments
  3. COSENTYX $588 34 payments
  4. LIBTAYO $438 20 payments
  5. TREMFYA $260 6 payments
  6. Enbrel $211 10 payments
  7. Cimzia $203 10 payments
  8. ADBRY $187 9 payments
  9. DUPIXENT $152 8 payments
  10. RINVOQ $151 8 payments
  11. Other $1,605 95 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

491

Median for Dermatology: 534

Drug cost

$68,102

Median for Dermatology: $67,151

Branded share of claims

6.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 14 $56,897
Fluorouracil Generic 42 $4,646
Clobetasol Propionate Generic 39 $1,666
Metronidazole Generic 16 $989
Triamcinolone Acetonide Generic 79 $836
Cephalexin Generic 158 $806
Clindamycin Phosphate Generic 18 $796
Betamethasone Dipropionate Generic 12 $388
Mupirocin Generic 61 $357
Ketoconazole Generic 23 $351

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$323,749

Of which drugs: $1,970

Medicare patients

753

Average age 76

Services billed

6,128

347 women, 406 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 45%
Diabetes 22%
Chronic kidney disease 22%
Ischemic heart disease 21%
Cancer 15%
Atrial fibrillation 14%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 56 $38

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
  • Novartis Pharmaceuticals Corporation $203
$203 — —
SKYRIZI
  • AbbVie, Inc. $136
$136 — —
ADBRY
  • LEO Pharma Inc. $110
$110 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $40
$40 — —
RINVOQ
  • AbbVie, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record